Suvarol 5 mg/10 mg apvalkotās tabletes Латвия - латвийски - Zāļu valsts aģentūra

suvarol 5 mg/10 mg apvalkotās tabletes

zaklady farmaceutyczne polpharma s.a., poland - amlodipinum, atorvastatinum - apvalkotā tablete - 5 mg/10 mg

Suvarol 5 mg/20 mg apvalkotās tabletes Латвия - латвийски - Zāļu valsts aģentūra

suvarol 5 mg/20 mg apvalkotās tabletes

zaklady farmaceutyczne polpharma s.a., poland - amlodipinum, atorvastatinum - apvalkotā tablete - 5 mg/20 mg

Bosentan Sandoz 125 mg apvalkotās tabletes Латвия - латвийски - Zāļu valsts aģentūra

bosentan sandoz 125 mg apvalkotās tabletes

sandoz d.d., slovenia - bosentāns - apvalkotās tabletes - 125 mg

Carmustine medac (previously Carmustine Obvius) Европейски съюз - латвийски - EMA (European Medicines Agency)

carmustine medac (previously carmustine obvius)

medac gesellschaft für klinische spezialpräparate mbh - karmustīns - hodgkin disease; lymphoma, non-hodgkin - antineoplastiski līdzekļi - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).

Alfentanil Kalceks 0,5 mg/ml šķīdums injekcijām/infūzijām Латвия - латвийски - Zāļu valsts aģentūra

alfentanil kalceks 0,5 mg/ml šķīdums injekcijām/infūzijām

kalceks, a/s, latvia - alfentanils - Šķīdums injekcijām/infūzijām - 0,5 mg/ml

Nexviadyme Европейски съюз - латвийски - EMA (European Medicines Agency)

nexviadyme

sanofi b.v. - avalglucosidase alfa - glikogēna uzglabāšanas slimības ii tipa - citas gremošanas trakta un metabolisma produkti, - nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with pompe disease (acid α-glucosidase deficiency).

Enjaymo Европейски съюз - латвийски - EMA (European Medicines Agency)

enjaymo

sanofi b.v. - sutimlimab - hemolysis; anemia, hemolytic, autoimmune - imūnsupresanti - enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (cad).

Tyruko Европейски съюз - латвийски - EMA (European Medicines Agency)

tyruko

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imūnsupresanti - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 un 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Invega Европейски съюз - латвийски - EMA (European Medicines Agency)

invega

janssen-cilag international nv - paliperidone - schizophrenia; psychotic disorders - psihoterapija - invega ir norādīts ārstēšanai šizofrēnijas pieaugušajiem un pusaudžiem par 15 gadiem un vecāki. invega ir indicēts, lai ārstētu schizoaffective traucējumi pieaugušajiem.

Yttriga Европейски съюз - латвийски - EMA (European Medicines Agency)

yttriga

eckert ziegler radiopharma gmbh - yttrium (90y) chloride - radionuklīdu attēlveidošana - diagnostikas radiofarmaceitiskie preparāti - jāizmanto tikai pārvadātāju molekulu radioloģiskajam marķējumam, kuri ir īpaši izstrādāti un atļauti radioaktīvai marķēšanai ar šo radionuklīdu. radiofarmaceitisko prekursoru, kas nav paredzēti tiešai lietošanai pacientiem.